

PA 1289972

REC'D 05 APR 2005

WIPO

PCT


THE UNITED STATES OF AMERICA**TO ALL TO WHOM THESE PRESENTS SHALL COME:****UNITED STATES DEPARTMENT OF COMMERCE****United States Patent and Trademark Office****March 03, 2005**

**THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A
FILING DATE UNDER 35 USC 111.**

APPLICATION NUMBER: 60/555,700**FILING DATE: March 24, 2004****PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

**By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS**



**T. LAWRENCE
Certifying Officer**



17691
U.S. PTO

Mail Stop Provisional Patent Application

PTO/SB/16 (6-95)
Approved for use through 04/11/98. OMB 0651-0037
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

PROVISIONAL APPLICATION COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION under 37 CFR 1.53 (c).

Docket Number		3665-92	Type a plus sign (+) inside this box →	+
INVENTOR(S)/APPLICANT(S)				
LAST NAME	FIRST NAME	MIDDLE INITIAL	RESIDENCE (CITY AND EITHER STATE OR FOREIGN COUNTRY)	
PHILIPPI ROUSSEAU ROSCHMANN	Anne Francis Elke		ST FARGEAU PONTIERRY, France SAVIGNY SUR ORGE, France CORBEIL ESSONE, France : :	

TITLE OF THE INVENTION (280 characters)

HUMAN OBESITY SUSCEPTIBILITY GENES ENCODING POLYPEPTIDES OF THE NEUROPEPTIDE Y FAMILY AND USES THEREOF

CORRESPONDENCE ADDRESS

Direct all correspondence to:



Customer Number:

23117

Type Customer Number here

Place Customer
Number Bar
Label Here →

22264 U.S. PTO
60/555700



ENCLOSED APPLICATION PARTS (check all that apply)



Specification

Number of Pages

36



Applicant claims "small entity" status.



Drawing(s)

Number of Sheets

1



"Small entity" statement attached.

Other (specify)

5 page Sequence Listing

METHOD OF PAYMENT (check one)



A check or money order is enclosed to cover the Provisional filing fees (\$160.00)/(\$80.00)



The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed; or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

PROVISIONAL
FILING FEE
AMOUNT (\$)

160.00

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.



No.



Yes, the name of the U.S. Government agency and the Government contract number are:

Respectfully submitted,
SIGNATURE

B. J. Sadoff

DATE

March 24, 2004

TYPED or PRINTED NAME

B. J. Sadoff

REGISTRATION NO.
(if appropriate)

36,663



Additional inventors are being named on separately numbered sheets attached hereto.

PROVISIONAL APPLICATION FILING ONLY

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Mail Stop Comments - Patents, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, and to the Office of Information and Regulatory Affairs, Office of Management and Budget (Project 0651-0037), Washington, DC 20503. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Provisional Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

829025

HUMAN OBESITY SUSCEPTIBILITY GENES ENCODING
POLYPEPTIDES OF THE NEUROPEPTIDE Y FAMILY AND
USES THEREOF

5

FIELD OF THE INVENTION

The present invention relates generally to the fields of genetics and medicine. The present invention more particularly discloses the identification of two human obesity
10 susceptibility genes, which can be used for the diagnosis and prevention of obesity and related disorders. The invention more specifically discloses that the pancreatic polypeptide (PPY) and peptide YY (PYY) genes on chromosome 17 and certain alleles thereof are related to susceptibility to obesity. The present invention relates to particular
15 mutations in the PPY and PYY genes and expression products, as well as to diagnostic tools and kits based on these mutations. The invention can be used in the diagnosis of predisposition to or protection from, detection, and prevention of coronary heart disease and metabolic disorders, including hypoalphalipoproteinemia, familial combined hyperlipidemia, insulin resistant syndrome X or multiple metabolic disorder, coronary artery disease, diabetes and dyslipidemia.

20

BACKGROUND OF THE INVENTION

Approximately three to eight percent of the total health costs of modern industrialized countries are currently due to the direct costs of obesity (Wolf, 1996). In Germany, the total costs (both direct and indirect) related to obesity and comorbid disorders were estimated at 21 billion German marks (29.4 US Dollar) in 1995 (Schneider, 1996). By
25 2030 these costs will rise by 50% even if the prevalence of obesity does not increase further.

Obesity is often defined simply as a condition of abnormal or excessive fat accumulation in adipose tissue, to the extent that health may be impaired. The underlying disease is the

process of undesirable positive energy balance and weight gain. An abdominal fat distribution is associated with higher health risks than a gynoid fat distribution.

The body mass index (BMI; kg/m²) provides the most useful, albeit crude, population-level measure of obesity. It can be used to estimate the prevalence of obesity within a population and the risks associated with it. However, BMI does not account for body composition or body fat distribution (WHO, 1998).

Table 1: Classification of overweight in adults according to BMI (WHO, 1998)

Classification	BMI (kg/m ²)	Risk of co-morbidities
Underweight	< 18.5	Low (but risks of other clinical problems increased)
Normal range	18.5 – 24.9	Average
Overweight	≥ 25	
Pre-obese	25 – 29.9	Increased
Obese class I	30 – 34.9	Moderate
Obese class II	35 – 39.9	Severe
Obese class III	≥ 40	Very severe

Obesity has also been defined using the 85th and 95th BMI-percentiles as cutoffs for definition of obesity and severe obesity. BMI-percentiles have been calculated within several populations; centiles for the German population based on the German National Nutrition Survey have been available since 1994 (Hebebrand et al., 1994, 1996). Because the WHO classification of the different weight classes can only be applied to adults, it has become customary to refer to BMI-percentiles for the definition of obesity in children and adolescents.

The recent rise in the prevalence of obesity is an issue of major concern for the health systems of several countries. According to reports of the Center of Disease Control and Prevention (CDC) there has been a dramatic increase in obesity in the United States during the past 20 years. In 1985 only a few states were participating in CDC's Behavioral Risk Factor Surveillance System (BRFSS) and providing obesity data. In 1991, four states were reporting obesity prevalence rates of 15-19 percent and no states reported rates at or above 20 percent. In 2002, 20 states have obesity prevalence rates of 15-19 percent; 29 states have rates of 20-24 percent; and one state reports a rate over 25 percent. Similar trends have been observed in other countries in Europe and South America.

Children and adolescents have not been exempt from this trend. Quite to the contrary, the increase in the USA has been substantial. Thus, between the 1960ies and 1990, overweight and obesity increased dramatically in 6 through to 17 year olds. The increments translate into relative increases of 40% using the 85th BMI-centile (calculated in the 1960ies) as a cutoff and 100% upon use of the 95th centile. In a cross sectional study of German children and adolescents treated as inpatients for extreme obesity between 1985 and 1995, a significant increase of the mean BMI of almost 2 kg/m² over this ten year period has been reported. Within this extreme group, the increments were most pronounced in the uppermost BMI ranges.

The mechanisms underlying this increase in the prevalence of obesity are unknown. Environmental factors have commonly been invoked as the underlying cause. Basically, both an increased caloric intake and a reduced level of physical activity have been discussed. In England the increase in obesity rates has been attributed to the latter mechanism. Thus, in this country, the average caloric intake even decreased somewhat within the last two decades, whereas indirect evidence stemming from the increases in hours spent watching television and from the average number of cars per household points to reduced levels of physical activity as the relevant causative factor.

Genetic factors have previously not been considered as a contributing cause. Quite to the contrary, the fact that the increased rates of obesity have been observed within the last

two decades has been viewed as evidence that genetic factors cannot be held responsible. However, it has been proposed that an increase in the rate of assortative mating could very well constitute a genetic contribution to the observed phenomenon. This hypothesis is based on evidence suggesting that stigmatisation of obese individuals represents a rather recent social phenomenon, thus invariably having led to increased rates of assortative mating. As a consequence, the offspring have a higher loading with both additive and non-additive genetic factors underlying obesity. Indeed, an exceedingly high rate of (deduced) assortative mating amongst the parents of extremely obese children and adolescents has been observed.

Potentially life-threatening, chronic health problems associated with obesity fall into four main areas: 1) cardiovascular problems, including hypertension, chronic heart disease and stroke, 2) conditions associated with insulin resistance, namely Non-Insulin Dependent Diabetes Mellitus (NIDDM), 3) certain types of cancers, mainly the hormonally related and large-bowel cancers, and 4) gallbladder disease. Other problems associated with obesity include respiratory difficulties, chronic musculo-skeletal problems, skin problems and infertility (WHO, 1998).

The main currently available strategies for treating these disorders include dietary restriction, increments in physical activity, pharmacological and surgical approaches. In adults, long term weight loss is exceptional using conservative interventions. Present pharmacological interventions typically induce a weight loss of between five and fifteen kilograms; if the medication is discontinued, renewed weight gain ensues. Surgical treatments are comparatively successful and are reserved for patients with extreme obesity and/or with serious medical complications.

Recently, a 10 year old massively obese girl, in whom a leptin deficiency mutation had been detected, was treated successfully with recombinant leptin. This is the first individual who therapeutically profited from the detection of the mutation underlying her morbid obesity.

Several twin studies have been performed to estimate heritability of the BMI, some of which have encompassed over 1000 twin pairs. The results have been very consistent: The intrapair correlations among monozygotic twins were typically between 0.6 and 0.8, independent of age and gender. In one study, the correlations for monozygotic and dizygotic twins were basically the same, independent of whether the twins had been reared apart or together. Heritability of the BMI was estimated at 0.7; non-shared environmental factors explained the remaining 30% of the variance. Surprisingly, shared environmental factors did not explain a substantial proportion of the variance. Both hypercaloric and hypocaloric alimentation lead to similar degrees of weight gain or loss among both members of monozygotic twin pairs, indicating that genetic factors regulate the effect of environmentally induced variation of energy availability on body weight. Metabolic reactions and changes in body fat distribution upon overeating and undereating are also under genetic control (reviewed in Hebebrand et al., 1998).

A large adoption study has revealed that the BMI of adoptees is correlated with that of their biological parents and not with the BMI of the adoptive parents. Depending on the family study, the correlation between the BMI of sibs is between 0.2 and 0.4. Parent-offspring correlations are typically slightly lower. Segregation analyses have repeatedly suggested a major recessive gene effect. Based on these analyses, sample size calculations have been performed based on both concordant and discordant approaches. In contrast to the expectations, the concordant sib-pair approach was superior; a lower number of families were required to achieve the same power.

Family studies based on extremely obese young index patients, either mother or father or both, have a BMI > 90th decile in the vast majority of the families. Based on index patients with a BMI > 95th centile, approximately 20% of the respective families have a sib with a BMI > 90th centile.

In conclusion, it is apparent that environmental factors interact with specific genotypes rendering an individual more or less susceptible to the development of obesity. Furthermore, despite the fact that major genes have been detected, it is necessary to

consider that the spectrum reaches from such major genes to genes with an only minor influence.

The discovery of the leptin gene at the end of 1994 (Zhang et al., 1994) has been followed by a virtual explosion of scientific efforts to uncover the regulatory systems underlying appetite and weight regulation. It is currently the fastest growing biomedical field. This upswing has also resulted in large scaled molecular genetic activities which, due to obvious clinical interest, are basically all related to obesity in humans, rodents and other mammals (Hebebrand et al., 1998).

In this respect, many genes in which mutations lead to the presently known monogenic forms of obesity have been cloned in rodents. Systemic consequences of these mutations are currently being analysed. These models have provided insights into the complex regulatory systems involved in body weight regulation, the best known of which includes leptin and its receptor.

In mice, but also in pigs, over 15 quantitative trait loci (QTL) have been identified that are most likely relevant in weight regulation (Chagnon et al., 2003).

In humans, four exceedingly rare autosomal recessive forms of obesity have been described as of 1997. Mutations in the genes encoding for leptin, leptin receptor, prohormone convertase 1 and pro-opiomelanocortin (POMC) have been shown to cause massive obesity of an early onset type, associated with hyperphagia. Distinct additional clinical (e.g. red hair, primary amenorrhea) and/or endocrinological abnormalities (e.g. markedly altered serum leptin levels, lack of ACTH secretion) pinpointed to the respective candidate genes. Both the monogenic animal models and the human monogenic forms have led to new insights into the complex system underlying body weight regulation.

Very recently, the first autosomal dominant form of obesity was described in humans. Two different mutations within the melanocortin-4 receptor gene (*MC4R*) were observed to lead to extreme obesity in probands heterozygous for these variants. In contrast to the

aforementioned findings, these mutations do not implicate readily obvious phenotypic abnormalities other than extreme obesity (Vaisse et al., 1998; Yeo et al., 1998). Interestingly, both groups detected the mutations by systematic screens in relatively small study groups (n=63 and n=43).

5

Hinney et al. (1999) screened the *MC4R* in a total of 492 obese children and adolescents. All in all, four individuals with two different mutations leading to haplo-insufficiency were detected. One was identical to that previously observed by Yeo et al. (1998). The other mutation, which was detected in three individuals, induced a stop mutation in the extracellular domain of the receptor. Approximately one percent of extremely obese individuals harbour haplo-insufficiency mutations in the *MC4R*. In addition to the two forms of haplo-insufficiency, Hinney et al. (1999) also detected additional mutations leading to both conservative and non-conservative amino acid exchanges. Interestingly, these mutations were mainly observed in the obese study group. The functional implications of these mutations are currently unknown.

10

15

The identification of individuals with *MC4R* mutations is interesting in the light of possible pharmacological interventions. Thus, intranasal application of adrenocorticotropin₄₋₁₀ (ACTH₄₋₁₀), representing a core sequence of all melanocortins, resulted in reduced weight, body fat mass and plasma leptin concentrations in healthy controls. The question arises as to how mutation carriers would react to this treatment, which could theoretically counterbalance their reduced receptor density.

20

The involvement of specific genes in weight regulation is further substantiated by data obtained from transgenic mice. For example, *MC4R* deficient mice develop early onset obesity (Huszar et al., 1997).

25

Different groups are conducting genome scans related to obesity or dependent phenotypes (BMI, leptin levels, fat mass, etc.). This approach appears very promising, because it is both systematic and model free. In addition, it has already been shown to be exceptionally successful. Thus, positive linkage results have been obtained even by analysing comparatively small study groups. More important, some findings have

30

already been replicated. Each of the following regions has been identified by at least two independent groups: chromosome 1p32, chromosome 2p21, chromosome 6p21, chromosome 10 and chromosome 20q13 (Chagnon et al., 2003).

5

SUMMARY OF THE INVENTION

The present invention now discloses the identification of two human obesity susceptibility genes, which can be used for the diagnosis, and prevention of obesity and related disorders. The invention more specifically demonstrates that the PPY and PYY genes on chromosome 17 and certain alleles thereof are related to susceptibility to obesity.

More particularly, the invention concerns several haplotypes and SNPs that are located in a chromosomal region on chromosome 17 including the PPY and PYY genes. Preferably, said haplotypes associated with obesity are comprised of SNP4, SNP5 and SNP6. In addition, said single SNPs each independently associated with obesity are SNP7 and SNP8.

The invention can be used in the diagnosis of predisposition to or protection from, detection, and/or prevention of obesity, coronary heart disease and metabolic disorders, including hypoalphalipoproteinemia, familial combined hyperlipidemia, insulin resistant syndrome X or multiple metabolic disorder, coronary artery disease, diabetes and dyslipidemia.

25

A particular object of this invention resides in a method of detecting the presence of or predisposition to obesity or an associated disorder in a subject, the method comprising detecting the presence of an alteration in the PPY and/or PYY gene locus in a sample from the subject, the presence of said alteration being indicative of the presence of or the predisposition to obesity or an associated disorder.

30

An additional particular object of this invention resides in a method of detecting the protection from obesity or an associated disorder in a subject, the method comprising detecting the presence of an alteration in the PPY and/or PYY gene locus in a sample from the subject, the presence of said alteration being indicative of the protection from obesity or an associated disorder.

Another particular object of this invention resides in a method of assessing the response of a subject to a treatment of obesity or an associated disorder, the method comprising detecting the presence of an alteration in the PPY and/or PYY gene locus in a sample from the subject, the presence of said alteration being indicative of a particular response to said treatment.

This invention also relates to a method for preventing obesity or an associated disorder in a subject, comprising detecting the presence of an alteration in the PPY and/or PYY gene locus in a sample from the subject, the presence of said alteration being indicative of the predisposition to obesity or an associated disorder; and, administering a prophylactic treatment against obesity or an associated disorder.

In a preferred embodiment, said alteration is one or several SNP(s) or a haplotype of SNPs associated with obesity. More preferably, said haplotype associated with obesity comprises or consists of SNP4, SNP5 and SNP6. More preferably, said SNP associated with obesity can be SNP7 or SNP8.

Preferably, the alteration in the PPY and/or PYY gene locus is determined by performing a hybridization assay, a sequencing assay, a microsequencing assay, an allele-specific amplification assay.

A particular aspect of this invention resides in compositions of matter comprising primers, probes, and/or oligonucleotides, which are designed to specifically detect at least one SNP or haplotype associated with obesity in the genomic region including the PPY or PYY gene, or a combination thereof. Preferably, said haplotype associated with

obesity are comprised of SNP4, SNP5 and SNP6. Preferably, said SNP associated with obesity is SNP7 or SNP8.

Another aspect of this invention resides in binding assays utilizing the PPY and PYY gene, PPY and PYY expression products, and/or antibodies thereto.

LEGEND TO THE FIGURES

Figure 1 : High density mapping using Genomic Hybrid Identity Profiling (GenomeHIP) A total of 2263 BAC clones with an average spacing of 1.2 Mega base pairs between clones representing the whole human genome were tested for linkage using GenomeHIP. Each point on the x-axis corresponds to a clone. Several clones are indicated by their library name for better orientation (e.g. BACA9ZF10). Significant evidence for linkage was calculated for clone BACA9ZF10 (p -value 1.7×10^{-5}). Suggestive evidence for linkage was calculated for clones BACA12ZA06 and BACA16ZF02 (p -value 2.1×10^{-5} and 7.3×10^{-5} , respectively). The whole linkage region is encompassing a region starting from 42214759 base pairs to 46697765 base pairs on human chromosome 17. The p -value 2×10^{-5} corresponding to the significance level for significant linkage and the p -value 3×10^{-4} corresponding to the significance level for suggestive linkage was used as a significance level for whole genome screens as proposed by Lander and Kruglyak (1995).

DETAILED DESCRIPTION OF THE INVENTION

The present invention discloses the identification of PPY and PYY as human obesity susceptibility genes. Various nucleic acid samples from 164 families with obesity were submitted to a particular GenomeHIP process. This process led to the identification of particular identical-by-descent fragments in said populations that are altered in obese subjects. By screening of the IBD fragments, the inventors identified the pancreatic polypeptide (PPY) and the peptide YY (PYY) gene as candidates for obesity and related

phenotypes. These genes are indeed present in the critical interval and express a functional phenotype consistent with a genetic regulation of obesity. Several SNPs located within the critical interval including the PPY and PYY genes were also identified, as being correlated to obesity in human subjects. Haplotypes comprising of
5 SNP4, SNP5 and SNP6 were found to be associated with obesity. In addition, SNP7 and SNP8 were each found to be independently associated with obesity.

The present invention thus proposes to use PPY and PYY genes for the diagnosis, and prevention of obesity and associated disorders.

10 DEFINITIONS

Obesity and metabolic disorders: Obesity shall be construed as any condition of
15 abnormal or excessive fat accumulation in adipose tissue, to the extent that health may be impaired. Associated disorders, diseases or pathologies include, more specifically, any metabolic disorders, including hypo-alphalipoproteinemia, familial combined hyperlipidemia, insulin resistant syndrome X or multiple metabolic disorder, coronary artery disease, diabetes mellitus and dyslipidemia. The invention may be used in various
20 subjects, particularly human, including adults, children and at the prenatal stage.

Within the context of this invention, the PPY and PYY gene locus designate all PPY and PYY sequences or products in a cell or organism, including PPY and PYY coding sequences, PPY and PYY non-coding sequences (e.g., introns), PPY and PYY
25 regulatory sequences controlling transcription and/or translation (e.g., promoter, enhancer, terminator, etc.), as well as all corresponding expression products, such as PPY and PYY RNAs (e.g., mRNAs) and PPY and PYY polypeptides (e.g., a pre-protein and a mature protein). The PPY and PYY gene locus also comprise surrounding sequences of the PPY and PYY gene which include SNPs that are in linkage
30 disequilibrium with SNPs located in the PPY and PYY gene. For example, the PPY and PYY locus comprises surrounding sequences comprising SNP4 to SNP8.

As used in the present application, the term "PPY gene" and the term "PYY gene" designate the human pancreatic polypeptide gene and the peptide YY gene, respectively, on human chromosome 17, as well as variants, analogs and fragments thereof, including alleles thereof (e.g., germline mutations) which are related to susceptibility to or protection from obesity and metabolic disorders. The PPY gene may also be referred to as the pancreatic icosapeptide, the PNP, or the pancreatic hormone precursor (pancreatic polypeptide) (PP) gene. The PYY gene may be referred to as the peptide YY precursor (PYY) (Peptide tyrosine tyrosine) gene.

The term "gene" shall be construed to include any type of coding nucleic acid, including genomic DNA (gDNA), complementary DNA (cDNA), synthetic or semi-synthetic DNA, as well as any form of corresponding RNA. The term gene particularly includes recombinant nucleic acids encoding PPY or PYY, i.e., any non naturally occurring nucleic acid molecule created artificially, e.g., by assembling, cutting, ligating or amplifying sequences. A PPY and PYY gene is typically double-stranded, although other forms may be contemplated, such as single-stranded. PPY and PYY genes may be obtained from various sources and according to various techniques known in the art, such as by screening DNA libraries or by amplification from various natural sources. Recombinant nucleic acids may be prepared by conventional techniques, including chemical synthesis, genetic engineering, enzymatic techniques, or a combination thereof. Suitable PPY gene sequences may be found on gene banks, such as Unigene Cluster for PPY (Hs.184604), Unigene Representative Sequence NM_002722, REFSEQ mRNAs: NM_002722, MIPS assembly: H33998S1, DOTS assembly: DT.208492, DT.100018387 and additional gene/cDNA sequences: BC032225, BC040033, M11726, M15788, X00491. Suitable PYY gene sequences may be found on gene banks, such as Unigene Cluster for PYY (Hs.169249), Unigene Representative Sequence NM_004160, REFSEQ mRNAs: NM_004160, MIPS assembly: H30710S1, H30710S2, DOTS assembly: DT.452118, DT.87046273 and additional gene/cDNA sequences: BC041057, D13897, D13899, D13902, L25648.1.

A PPY polypeptide designates any protein or polypeptide encoded by a PPY gene as disclosed above. A PYY polypeptide designates any protein or polypeptide encoded by a

PYY gene as disclosed above. The term "polypeptide" refers to any molecule comprising a stretch of amino acids. This term includes molecules of various length, such as peptides and proteins. The polypeptide may be modified, such as by glycosylations and/or acetylations and/or chemical reaction or coupling, and may contain one or several
5 non-natural or synthetic amino acids.

A fragment of a PYY or PPY gene designates any portion of at least about 8 consecutive nucleotides of a sequence as disclosed above, preferably at least about 15, more preferably at least about 20 nucleotides, further preferably of at least 30 nucleotides.

10 Fragments include all possible nucleotide length between 8 and 100 nucleotides, preferably between 15 and 100, more preferably between 20 and 100.

Typical stringent hybridisation conditions include temperatures above 30° C, preferably above 35°C, more preferably in excess of 42°C, and/or salinity of less than about 500
15 mM, preferably less than 200 mM. Hybridization conditions may be adjusted by the skilled person by modifying the temperature, salinity and/or the concentration of other reagents such as SDS, SSC, etc.

20 DIAGNOSIS

The invention now provides diagnosis methods based on a monitoring of the PPY and/or PYY gene locus in a subject. Within the context of the present invention, the term 'diagnosis' includes the detection, monitoring, dosing, comparison, etc., at various
25 stages, including early, pre-symptomatic stages, and late stages, in adults, children and pre-birth. Diagnosis typically includes the prognosis, the assessment of a predisposition or risk of development or protection, the characterization of a subject to define most appropriate treatment (pharmaco-genetics), etc.

30 A particular object of this invention resides in a method of detecting the presence of or predisposition to obesity or an associated disorder in a subject, the method comprising

(i) providing a sample from the subject and (ii) detecting the presence of an alteration in the PPY and/or PYY gene locus in said sample.

5 A further object of this invention resides in a method of detecting the presence of or predisposition to obesity or an associated disorder in a subject, the method comprising detecting the presence of an alteration in the PPY and/or PYY gene locus in a sample from the subject, the presence of said alteration being indicative of the presence of or the predisposition to obesity or an associated disorder.

10 Another particular object of this invention resides in a method of detecting the protection from obesity or an associated disorder in a subject, the method comprising detecting the presence of an alteration in the PPY and/or PYY gene locus in a sample from the subject, the presence of said alteration being indicative of the protection from obesity or an associated disorder.

15 In a preferred embodiment, said alteration is one or several SNP(s) or a haplotype of SNPs associated with obesity. More preferably, said haplotype associated with obesity comprises or consists of SNP4, SNP5 and SNP6. Said SNP associated with obesity can be SNP7 or SNP8.

20 Another particular object of this invention resides in a method of assessing the response of a subject to a treatment of obesity or an associated disorder, the method comprising (i) providing a sample from the subject and (ii) detecting the presence of an alteration in the PPY and/or PYY gene locus in said sample.

25 A further object of this invention resides in a method of assessing the response of a subject to a treatment of obesity or an associated disorder in a subject, the method comprising detecting the presence of an alteration in the PPY and/or PYY gene locus in a sample from the subject, the presence of said alteration being indicative of a particular
30 response to said treatment.

In a preferred embodiment, said alteration is one or several SNP(s) or an haplotype of SNPs associated with obesity. More preferably, said haplotype associated with obesity comprises or consists of SNP4, SNP5 and SNP6. Said SNP associated with obesity can be SNP7 or SNP8.

5

This invention also relates to a method of determining the efficacy of a treatment of obesity or an associated disorder, the method comprising (i) providing a sample from the subject during or after said treatment, (ii) determining the PPY and/or PYY gene locus status in said sample and (iii) comparing said PPY and/or PYY gene locus status to a
10 reference PPY and/or PYY gene locus status in a sample from said subject prior to or at an earlier stage of the treatment.

In an additional embodiment, the invention concerns a method for preventing obesity or an associated disorder in a subject, comprising detecting the presence of an alteration in
15 the PPY and/or PYY gene locus in a sample from the subject, the presence of said alteration being indicative of the predisposition to obesity or an associated disorder; and, administering a prophylactic treatment against obesity or an associated disorder. Said prophylactic treatment can be an administration of a drug and/or a diet.

20 An alteration in the PPY and/or PYY gene locus may be any form of mutation(s), deletion(s), rearrangement(s) and/or insertion(s) in the coding and/or non-coding region of the locus, alone or in various combination(s). Mutations more specifically include point mutations. Deletions may encompass any region of two or more residues in a coding or non-coding portion of the gene locus, such as from two residues up to the
25 entire gene or locus. Typical deletions affect smaller regions, such as domains (introns) or repeated sequences or fragments of less than about 50 consecutive base pairs, although larger deletions may occur as well. Insertions may encompass the addition of one or several residues in a coding or non-coding portion of the gene locus. Insertions may typically comprise an addition of between 1 and 50 base pairs in the gene locus.
30 Rearrangement includes inversion or translocation of sequences. The PPY and/or PYY gene locus alteration may result in the creation of stop codons, frameshift mutations, amino acid substitutions, particular RNA splicing or processing, product instability,

truncated polypeptide production, etc. The alteration may result in the production of a PPY and/or PYY polypeptide with altered function, stability, targeting or structure. The alteration may also cause a reduction in protein expression or, alternatively, an increase in said production.

5

In a particular embodiment of the method according to the present invention, the alteration in the PPY and/or PYY gene locus is selected from a point mutation, a deletion and an insertion in the PPY and/or PYY gene or corresponding expression product, more preferably a point mutation and a deletion. The alteration may be determined at the level of the PPY and/or PYY gDNA, RNA or polypeptide.

10

In this regard, the present invention now discloses several SNPs located in the genomic region ranging from 42491617 to 42561112 including the PPY gene located at 42493338 to 42494188 base pairs and the PYY gene located at 42505281 to 42506462 base pairs, which are associated with obesity. The indicated nucleotide positions are based on the current sequence of Build34 obtained from NCBI. These point mutations (or single nucleotide alterations) are reported in the following Table 2:

15

Table 2

Nucleotide position in genomic sequence of chromosome 17	SNP identity	dbSNP reference	Polymorphism	Position in locus	Sequence reference
42491642	SNP4	rs231474	G/T	5' of PPY locus	SEQ ID No 1
42493636	SNP5	rs231473	A/G	Intron of PPY locus	SEQ ID No 2
42498976	SNP6	rs151196	A/G	3' of PPY locus and 5' of PYY locus	SEQ ID No 3
42547814	SNP7	rs1731902	C/T	3' of PYY locus	SEQ ID No 4
42561137	SNP8	rs186636	C/T	3' of PYY locus	SEQ ID No 5

20

These point mutations have been detected in subjects having obesity. Haplotypes were constructed for SNP4, SNP5 and SNP6 to determine the naturally occurring phase for

each possible SNP combination. These haplotypes were then used to test for association between all the resulting haplotypes derived from combinations of the individual alleles and obesity. The results show that haplotypes comprising SNP4, SNP5 and SNP6 (see Table 2 above) were associated with obesity (Table 4).

5

In addition, SNP7 and SNP8 were each independently tested for association with obesity. The results show that both SNPs (see Table 2 above) are each independently associated with obesity (Table 4).

10 In a first variant, the method of the present invention comprises detecting the presence of an altered PPY and/or PYY gene sequence. This can be performed by sequencing all or part of the PPY and/or PYY gene, polypeptide or RNA, by selective hybridisation or by selective amplification, for instance.

15 A more specific embodiment comprises detecting the presence of a SNP as disclosed in Table 2 in the genomic region including the PPY and PYY gene sequence of a subject.

In another variant, the method comprises detecting the presence of an altered PPY and/or PYY RNA expression. Altered RNA expression includes the presence of an altered RNA
20 sequence, the presence of an altered RNA splicing or processing, the presence of an altered quantity of RNA, etc. These may be detected by various techniques known in the art, including by sequencing all or part of the PPY and/or PYY RNA or by selective hybridisation or selective amplification of all or part of said RNA, for instance.

25 In a further variant, the method comprises detecting the presence of an altered PPY and/or PYY polypeptide expression. Altered PPY or PYY polypeptide expression includes the presence of an altered polypeptide sequence, the presence of an altered quantity of PPY or PYY polypeptide, the presence of an altered tissue distribution, etc. These may be detected by various techniques known in the art, including by sequencing
30 and/or binding to specific ligands (such as antibodies), for instance.

As indicated above, various techniques known in the art may be used to detect or quantify altered PPY and PYY gene or RNA expression or sequence, including sequencing, hybridisation, amplification and/or binding to specific ligands (such as antibodies). Other suitable methods include allele-specific oligonucleotide (ASO), allele-specific amplification, Southern blot (for DNAs), Northern blot (for RNAs), single-stranded conformation analysis (SSCA), PFGE, fluorescent in situ hybridization (FISH), gel migration, clamped denaturing gel electrophoresis, heteroduplex analysis, RNase protection, chemical mismatch cleavage, ELISA, radio-immunoassays (RIA) and immuno-enzymatic assays (IEMA).

Some of these approaches (e.g., SSCA and CGGE) are based on a change in electrophoretic mobility of the nucleic acids, as a result of the presence of an altered sequence. According to these techniques, the altered sequence is visualized by a shift in mobility on gels. The fragments may then be sequenced to confirm the alteration.

Some others are based on specific hybridisation between nucleic acids from the subject and a probe specific for wild-type or altered PPY or PYY gene or RNA. The probe may be in suspension or immobilized on a substrate. The probe is typically labelled to facilitate detection of hybrids.

Some of these approaches are particularly suited for assessing a polypeptide sequence or expression level, such as Northern blot, ELISA and RIA. These latter require the use of a ligand specific for the polypeptide, more preferably of a specific antibody.

In a particular, preferred, embodiment, the method comprises detecting the presence of an altered PPY and/or PYY gene expression profile in a sample from the subject. As indicated above, this can be accomplished more preferably by sequencing, selective hybridisation and/or selective amplification of nucleic acids present in said sample.

Sequencing:

Sequencing can be carried out using techniques well known in the art, using automatic sequencers. The sequencing may be performed on the complete PPY and/or PYY gene

or, more preferably, on specific domains thereof, typically those known or suspected to carry deleterious mutations or other alterations.

Amplification

- 5 Amplification is based on the formation of specific hybrids between complementary nucleic acid sequences that serve to initiate nucleic acid reproduction.

Amplification may be performed according to various techniques known in the art, such as by polymerase chain reaction (PCR), ligase chain reaction (LCR), strand displacement
10 amplification (SDA) and nucleic acid sequence based amplification (NASBA). These techniques can be performed using commercially available reagents and protocols. Preferred techniques use allele-specific PCR or PCR-SSCP. Amplification usually requires the use of specific nucleic acid primers, to initiate the reaction.

- 15 In this regard, a particular object of this invention resides in a nucleic acid primer useful for amplifying sequences from the PPY gene or locus including surrounding regions. Such primers are preferably complementary to, and hybridize specifically to nucleic acid sequences in the PPY gene locus. Particular primers are able to specifically hybridise with a portion of the PPY gene locus that flank a target region of said locus, said target
20 region being altered in certain subjects having obesity or associated disorders. Examples of such target regions are provided in Table 2 above.

Another particular object of this invention resides in a nucleic acid primer useful for amplifying sequences from the PYY gene or locus including surrounding regions. Such
25 primers are preferably complementary to, and hybridize specifically to nucleic acid sequences in the PYY gene locus. Particular primers are able to specifically hybridise with a portion of the PYY gene locus that flank a target region of said locus, said target region being altered in certain subjects having obesity or associated disorders. Examples of such target regions are provided in Table 2 above.

30

In a more specific embodiment, the invention relates to a nucleic acid primer, wherein said primer is complementary to and hybridizes specifically to a portion of a PPY coding

sequence (e.g., gene or RNA), wherein said portion is altered in certain subjects having obesity or associated disorders. In this regard, particular primers of this invention are specific for altered sequences in a PPY gene or RNA. By using such primers, the detection of an amplification product indicates the presence of an alteration in the PPY gene locus. In contrast, the absence of amplification product indicates that the specific alteration is not present in the sample.

In a more specific embodiment, the invention also relates to a nucleic acid primer, wherein said primer is complementary to and hybridizes specifically to a portion of a PYY coding sequence (e.g., gene or RNA), wherein said portion is altered in certain subjects having obesity or associated disorders. In this regard, particular primers of this invention are specific for altered sequences in a PYY gene or RNA. By using such primers, the detection of an amplification product indicates the presence of an alteration in the PYY gene locus. In contrast, the absence of amplification product indicates that the specific alteration is not present in the sample.

A further aspect of this invention includes a pair of nucleic acid primers, wherein said pair comprises a sense and a reverse primer, and wherein said sense and reverse primer specifically amplify a PYY gene or RNA or a target region thereof, said target region being altered in certain subjects having obesity or associated disorders.

A further aspect of this invention also includes a pair of nucleic acid primers, wherein said pair comprises a sense and a reverse primer, and wherein said sense and reverse primer specifically amplify a PYY gene or RNA or a target region thereof, said target region being altered in certain subjects having obesity or associated disorders.

Typical primers of this invention are single-stranded nucleic acid molecules of about 5 to 60 nucleotides in length, more preferably of about 8 to about 25 nucleotides in length. The sequence can be derived directly from the sequence of the PPYR and PYY gene locus, respectively. Perfect complementarity is preferred, to ensure high specificity. However, certain mismatches may be tolerated.

Selective hybridization

Hybridization detection methods are based on the formation of specific hybrids between complementary nucleic acid sequences that serve to detect nucleic acid sequence alteration(s).

5

A particular detection technique involves the use of a nucleic acid probe specific for wild-type or altered PPY gene or RNA and/or the use of a nucleic acid probe specific for wild-type or altered PYY gene or RNA, followed by the detection of the presence of a hybrid. The probe may be in suspension or immobilized on a substrate or support (as in
10 nucleic acid array or chips technologies). The probe is typically labelled to facilitate detection of hybrids.

In this regard, a particular embodiment of this invention comprises contacting the sample from the subject with a nucleic acid probe specific for an altered PPY gene locus and/or
15 contacting the sample from the subject with a nucleic acid probe specific for an altered PYY gene locus, and assessing the formation of an hybrid. In a particular, preferred embodiment, the method comprises contacting simultaneously the sample with a set of probes that are specific, respectively, for wild type PPY gene locus and for various altered forms thereof. In a particular, preferred embodiment, the method also comprises
20 contacting simultaneously the sample with a set of probes that are specific, respectively, for wild type PYY and for various altered forms thereof. In this embodiment, it is possible to detect directly the presence of various forms of alterations in the PPY and/or PYY gene locus in the sample. Also, various samples from various subjects may be treated in parallel.

25

A further particular object of this invention resides in a nucleic acid probe specific for a PPY and/or PYY gene or RNA. Within the context of this invention, a probe refers to a polynucleotide sequence which is complementary to and capable of specific hybridisation with a (target portion of a) PPY and/or PYY gene or RNA, and which is
30 suitable for detecting polynucleotide polymorphisms associated with PPY and/or PYY alleles which predispose or protect to or are associated with obesity or metabolic disorders. Probes are preferably perfectly complementary to the PPY and/or PYY gene,

RNA, or target portion thereof. Probes typically comprise single-stranded nucleic acids of between 8 to 1000 nucleotides in length, for instance of between 10 and 800, more preferably of between 15 and 700, typically of between 20 and 500. It should be understood that longer probes may be used as well. A preferred probe of this invention is
5 a single stranded nucleic acid molecule of between 8 to 500 nucleotides in length, which can specifically hybridise to a region of a PPY and/or PYY gene or RNA that carries an alteration.

A specific embodiment of this invention is a nucleic acid probe specific for an altered
10 (e.g., a mutated) PPY and/or PYY gene or RNA, i.e., a nucleic acid probe that specifically hybridises to said altered PPY and/or PYY gene or RNA and essentially does not hybridise to a PPY and/or PYY gene or RNA lacking said alteration. Specificity indicates that hybridisation to the target sequence generates a specific signal which can be distinguished from the signal generated through non-specific hybridisation.
15 Perfectly complementary sequences are preferred to design probes according to this invention. It should be understood, however, that certain mismatch may be tolerated, as long as the specific signal may be distinguished from non-specific hybridisation.

Particular examples of such probes are nucleic acid sequences complementary to a target
20 portion of the genomic region including the PPY and PYY gene or RNA carrying a point mutation as listed in Table 2 above. More particularly, the probes can comprise a sequence selected from the group consisting of SEQ ID Nos 1-5 or a fragment thereof comprising the SNP or a complementary sequence thereof.

25 The sequence of the probes can be derived from the sequences of the PPY and/or PYY gene and RNA as provided in the present application. Nucleotide substitutions may be performed, as well as chemical modifications of the probe. Such chemical modifications may be accomplished to increase the stability of hybrids (e.g., intercalating groups) or to label the probe. Typical examples of labels include, without limitation, radioactivity,
30 fluorescence, luminescence, enzymatic labelling, etc.

Specific Ligand Binding

As indicated above, alteration in the PPY or PYY gene locus may also be detected by screening for alteration(s) in PPY or PYY polypeptide sequence or expression levels. In this regard, a specific embodiment of this invention comprises contacting the sample
5 with a ligand specific for a PPY and/or PYY polypeptide and determining the formation of a complex.

Different types of ligands may be used, such as specific antibodies. In a specific embodiment, the sample is contacted with an antibody specific for a PPY or PYY
10 polypeptide and the formation of an immune complex is determined. Various methods for detecting an immune complex can be used, such as ELISA, radio-immunoassays (RIA) and immuno-enzymatic assays (IEMA).

Within the context of this invention, an antibody designates a polyclonal antibody, a
15 monoclonal antibody, as well as fragments or derivatives thereof having substantially the same antigen specificity. Fragments include Fab, Fab'2, CDR regions, etc. Derivatives include single-chain antibodies, humanized antibodies, poly-functional antibodies, etc.

An antibody specific for a PPY or PYY polypeptide designates an antibody that
20 selectively binds a PPY or PYY polypeptide, i.e., an antibody raised against a PPY or PYY polypeptide or an epitope-containing fragment thereof. Although non-specific binding towards other antigens may occur, binding to the target PPY or PYY polypeptide occurs with a higher affinity and can be reliably discriminated from non-specific binding. Preferred antibodies are specific for wild-type PPY or PYY
25 polypeptide or for particular altered forms thereof. Preferred embodiments of this invention use antibodies specific for altered forms of PPY and/or PYY polypeptides, e.g., mutated, truncated or extended polypeptides. In particular, altered PPY or PYY polypeptides may comprise a specific domain resulting from a frameshift mutation in the coding region. Antibodies specific for said domain allow the detection of the presence of
30 such altered polypeptides in a sample. The ligand may be used in soluble form, or coated on a surface or support.

In a specific embodiment, the method comprises contacting a sample from the subject with (a support coated with) an antibody specific for an altered form of a PPY or PYY polypeptide, and determining the presence of an immune complex. In a particular embodiment, the sample may be contacted simultaneously, or in parallel, or sequentially, with various (supports coated with) antibodies specific for different forms of a PPY or PYY polypeptide, such as a wild-type and various altered forms thereof.

The diagnosis methods can be performed in vitro, ex vivo or in vivo, preferably in vitro or ex vivo. They use a sample from the subject, to assess the status of the PPY and/or PYY gene locus. The sample may be any biological sample derived from a subject, which contains nucleic acids or polypeptides. Examples of such samples include fluids, tissues, cell samples, organs, biopsies, etc. Most preferred samples are blood, plasma, saliva, urine, seminal fluid, etc. Prenatal diagnosis may also be performed by testing foetal cells or placental cells, for instance. The sample may be collected according to conventional techniques and used directly for diagnosis or stored. The sample may be treated prior to performing the method, in order to render or improve availability of nucleic acids or polypeptides for testing. Treatments include, for instant, lysis (e.g., mechanical, physical, chemical, etc.), centrifugation, etc. Also, the nucleic acids and/or polypeptides may be pre-purified or enriched by conventional techniques, and/or reduced in complexity. Nucleic acids and polypeptides may also be treated with enzymes or other chemical or physical treatments to produce fragments thereof. Considering the high sensitivity of the claimed methods, very few amounts of sample are sufficient to perform the assay.

As indicated, the sample is preferably contacted with reagents such as probes, primers or ligands in order to assess the presence of an altered PPY and/or PYY gene locus. Contacting may be performed in any suitable device, such as a plate, tube, well, glass, etc. In specific embodiments, the contacting is performed on a substrate coated with the reagent, such as a nucleic acid array or a specific ligand array. The substrate may be a solid or semi-solid substrate such as any support comprising glass, plastic, nylon, paper, metal, polymers and the like. The substrate may be of various forms and sizes, such as a slide, a membrane, a bead, a column, a gel, etc. The contacting may be made under any

condition suitable for a complex to be formed between the reagent and the nucleic acids or polypeptides of the sample.

5 The finding of an altered PPY or PYY polypeptide, RNA or DNA in the sample is indicative of the presence of an altered PPY or PYY gene locus in the subject, which can be correlated to the presence, predisposition or stage of progression of obesity or metabolic disorders. For example, an individual having a germline PPY and/or PYY mutation has an increased risk of developing obesity or metabolic disorders. The determination of the presence of an altered PPY and/or PYY gene locus in a subject also
10 allows the design of appropriate therapeutic intervention, which is more effective and customized. Also, this determination at the pre-symptomatic level allows a preventive regimen to be applied.

15 Further aspects and advantages of the present invention will be disclosed in the following experimental section, which should be regarded as illustrative and not limiting the scope of the present application.

20 EXAMPLES

1. Identification of an obesity susceptibility locus on human chromosome 17

25 A. GenomeHIP platform to identify the chromosome 17 susceptibility genes

The GenomeHIP platform was applied to allow rapid identification of two obesity susceptibility genes.

Briefly, the technology consists of forming pairs from the DNA of related individuals.
30 Each DNA is marked with a specific label allowing its identification. Hybrids are then formed between the two DNAs. A particular process (WO00/53802) is then applied that selects all fragments identical-by-descent (IBD) from the two DNAs in a multi step

procedure. The remaining IBD enriched DNA is then scored against a BAC clone derived DNA microarray that allows the positioning of the IBD fraction on a chromosome.

- 5 The application of this process over many different families results in a matrix of IBD fractions for each pair from each family. Statistical analyses then calculate the minimal IBD regions that are shared between all families tested. Significant results (p-values) are evidence for linkage of the positive region with the trait of interest (here obesity). The linked interval can be delimited by the two most distant clones showing significant p-
10 values.

In the present study, 164 families of German origin (178 independent sib-pairs) concordant for massive obesity (as defined by a body mass index > 90th%ile) were submitted to the GenomeHIP process. The resulting IBD enriched DNA fractions were
15 then labelled with Cy5 fluorescent dyes and hybridised against a DNA array consisting of 2263 BAC clones covering the whole human genome with an average spacing of 1.2 Mega base pairs. Non-selected DNA labelled with Cy3 was used to normalise the signal values and compute ratios for each clone. Clustering of the ratio results were then performed to determine the IBD status for each clone and pair.

20 By applying this procedure, several BAC clones spanning an approximately 4.5 mega-base region on chromosome 17 (bases 42200000 to 46700000) were identified, that showed significant (p-value 1.70E-05) or suggestive (p-value >2E-05) evidence for linkage to obesity (Table 3).

25 Table 3: Linkage results for chromosome 17 in the region of PPY and PYY: Indicated is the region correspondent to 3 BAC clones with evidence for linkage. The start and stop positions of the clones correspond to their genomic location based on NCBI Build34 sequence respective to the start of the chromosome (p-ter).

30

Table 3

Human chromo some	Clone	Proportion of informative pairs	p-value	Start	Stop

17	BACA16ZA02v	0.81	3.10E-02		
17	BACA24ZH05v	0.84	3.70E-03		42214759
17	BACA9ZF10v	0.88	1.70E-05**	44710426	44872488
17	BACA12ZA06v	0.88	2.10E-05*	45770413	45958511
17	BACA16ZF02v	0.87	7.30E-05*	46470465	46697765
17	BACA3ZB03v	0.89	2.00E-03		

B. Identification of two obesity susceptibility genes on chromosome 17

- 5 By screening the aforementioned 4.5 mega-base chromosomal region, we identified the pancreatic polypeptide (PPY) and peptide YY (PYY) genes as candidates for obesity and related phenotypes. These genes are indeed present in the critical interval, with evidence for linkage delimited by the clones outlined in Table 3 above.
- 10 Hort et al. (1995) showed that the PPY gene encoding a predicted 95-amino acid sequence polypeptide (mRNA 425 bp) and the PYY gene encoding a predicted 97-amino acid sequence polypeptide (mRNA 582 bp) are located approximately 10 kb apart on 17q21.1. The peptides encoded by the two genes, pancreatic polypeptide (PP) and peptide YY (PYY), respectively, belong to the neuropeptide Y (NPY) family of peptides
- 15 displaying high sequence homology. Based on sequence comparisons between the three genes it has been concluded that NPY and PYY are the result of a gene duplication event, and that a subsequent tandem duplication produced the PPY gene (Hort et al. 1995).
- 20 Multiple receptor subtypes with different affinities for these three endogenous peptides have been identified. NPY and PYY have highest affinity for the Y1, Y2, and Y5 receptors while PP is the endogenous ligand for the Y4 site (Michel et al., 1998). An alternate endogenous form of PYY, PYY(3-36), demonstrates increased affinity for the Y2 site that is thought to be primarily a presynaptic receptor found on NPY expressing
- 25 neurons (Michel et al., 1998).

Multiple actions of PP and PYY in food intake have now been described in rodents as well as humans.

Peripheral administration of PP to rodents has been shown to reduce food intake (Asakawa et al., 2002). Intravenous infusion of PP caused a sustained decrease in both appetite and food intake in healthy volunteers (Batterham et al., 2003).

5

Batterham et al. (2002) demonstrated that peripheral injection of PYY(3-36) in rats inhibits food intake and reduces weight gain. PYY(3-36) also inhibits food intake in mice but not in Y2r-null mice, which suggests that the anorectic effect requires the Y2 receptor. In humans, infusion of normal postprandial concentrations of PYY(3-36) significantly decreased appetite and reduced food intake by 33% over 24 hours (Batterham et al., 2002). Thus, postprandial elevation of PYY(3-36) may act through the arcuate nucleus Y2R to inhibit feeding in a gut-hypothalamic pathway.

10

Furthermore, PYY reduces food intake by modulating appetite circuits in the hypothalamus. Batterham et al. (2003) found that obese subjects are not resistant to the anorectic effects of PYY. Endogenous PYY levels were low in obese subjects, suggesting that PYY deficiency may contribute to the pathogenesis of obesity.

15

Taken together, the linkage results provided in the present application, identifying the human PPY and PYY genes in the critical interval of genetic alterations linked to obesity on chromosome 17, with its involvement in the NPY/PP signalling pathways involved in the control of food intake and energy expenditure, the inventors conclude that alterations (e.g., mutations and/or polymorphisms) in the PPY and/or PYY gene or its regulatory sequences may contribute to the development of human obesity and represent a novel target for diagnosis.

20

25

2. Association study

564 individuals with extreme, early onset obesity (cases) and 328 healthy individuals (controls) were included in the association study to test for association between a marker allele(s), haplotype and/or genotype and obesity.

30

A total of 5 single nucleotide polymorphisms (SNPs) covering the chromosomal region containing the PYY and PPY gene plus the surrounding 5' and 3' regions were selected for genotyping.

Haplotypes were constructed for SNP4, SNP5 and SNP6 to identify the phase for all SNPs using the PHASE program (version: 2.0; Stephens et al., 2001). The distribution of haplotypes was determined in patients and compared to the distribution of haplotypes in the control group.

The statistical analysis of the distribution of the haplotypes of SNP4, SNP5 and SNP6 between the obese patients and the controls revealed a correlation to obesity ($p = 0.02$). Haplotypes T-A-G (25.98% versus 23.74%) and T-A-A (20.73% versus 20.02%) were observed with a higher frequency in the obese individuals (cases) compared to the controls as shown in Table 4. Haplotypes T-G-G (0.02% versus 0.26%), G-G-G (52.48% versus 54.01%), G-G-A (0.77% versus 1.70%), G-A-G (0.01% versus 0.21%), and G-A-A (0.01% versus 0.06%) were under-represented in the obese patients compared to the controls.

Table 4: Distribution of haplotypes for SNP4, SNP5 and SNP6 in cases and controls.

Haplotype #	Haplotype SNP4-SNP5-SNP6	% cases	% controls
HAPLO:1	T-G-G	0.02	0.26
HAPLO:2	T-A-G	25.98	23.74
HAPLO:3	T-A-A	20.73	20.02
HAPLO:4	G-G-G	52.48	54.01
HAPLO:5	G-G-A	0.77	1.70
HAPLO:6	G-A-G	0.01	0.21
HAPLO:7	G-A-A	0.01	0.06

The distribution of the alleles of SNP7 and SNP8 were each independently compared between the patients and controls. Based on the distribution of the alleles of each SNP in the patients and controls, odds ratios and corresponding confidence intervals were calculated to measure the extent of the association. An odds ratio of greater than 1 means

that the tested genetic marker is associated with the disease and might therefore increase the susceptibility to disease. There is a negative association if the odds ratio is smaller than 1 and the tested genetic marker might help protecting from the disease.

5 The results of this analysis show that certain alleles of SNP7 and SNP8 are each independently associated with obesity. A higher frequency of allele C of SNP7 was observed in the patients compared to controls (0.42 versus 0.37) resulting in an odds ratio of 1.24 (95% CI:1.01-1.51, $p=0.0395$) for individuals who are carrying allele C compared to those who are carrying allele T. The allele C of SNP8 was also more often
10 present in patients compared to controls (0.39 versus 0.34) resulting in an odds ratio of 1.24 (95% CI: 1.02-1.52, $p=0.0351$) for individuals who are carrying allele C compared to those who are carrying allele T. In addition, a higher frequency of the homozygous CC genotype was observed for both SNPs in the patients compared to the controls (0.17 versus 0.13 for SNP7 and 0.14 versus 0.10 for SNP8). This resulted in an odds ratio of
15 1.56 (95% CI: 1.01-2.40, $p=0.0425$) for carriers of genotype CC of SNP7 compared to carriers of genotype TT. An odds ratio of 1.60 (95% CI: 1.01-2.52, $p=0.0422$) was determined for carriers of genotype CC of SNP8 compared to carriers of genotype TT.

The results also show that the alleles T of SNP7 and SNP8 are negatively associated
20 with obesity. A lower frequency of allele T of SNP7 was observed in the patients compared to controls (0.58 versus 0.63) resulting in an odds ratio of 0.81 (95% CI:0.66-0.99, $p=0.0395$) for individuals who are carrying allele T compared to those who are carrying allele C. The allele T of SNP8 was also more often under-represented in patients compared to controls (0.61 versus 0.66) resulting in an odds ratio of 0.81 (95%
25 CI: 0.66-0.99, $p=0.0351$) for carriers of this allele compared to carriers of allele C. In addition, a lower frequency of the homozygous TT genotype was observed for both SNPs in the patients compared to the controls (0.33 versus 0.39 for SNP7 and 0.37 versus 0.43 for SNP8). This resulted in an odds ratio of 0.64 (95% CI: 0.42-0.99, $p=0.0425$) for carriers of genotype TT of SNP7 compared to carriers of genotype CC.
30 An odds ratio of 0.63 (95% CI: 0.40-0.99, $p=0.0423$) was determined for carriers of genotype TT of SNP8 compared to carriers of genotype CC.

REFERENCES

- Asakawa A, Inui A, Yuzuriha H et al. (2003) Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. *Gastroenterology* 124(5): 1325-1336.
- 5 Batterham RL, Cowley MA, Small CJ et al. (2002) Gut hormone PYY(3-36) physiologically inhibits food intake. *Nature* 418(6898): 650-654.
- Batterham RL, Cohen MA, Ellis SM et al. (2003) Inhibition of food intake in obese subjects by peptide YY3-36. *N Engl J Med* 349(10): 941-948.
- 10 Batterham RL, Le Roux CW, Cohen MA et al. (2003) Pancreatic polypeptide reduces appetite and food intake in humans. *J Clin Endocrinol Metab* 88(8): 3989-3992.
- Chagnon YC, Rankinen T, Snyder EE et al. (2003) The human obesity gene map : The 2002 update. *Obes Res.* 11(3):313-367.
- Hebebrand J, Hescker H, Himmelmann GW, Schäfer H, Renschmidt H (1994)
- 15 Percentiles for the body mass index based on data of the German national nutrition survey and a review of relevant factors with an influence on body weight. *Aktuelle Ernährungsmedizin* 19: 259-265.
- Hebebrand J, Himmelmann GW, Hescker H, Schäfer H, Renschmidt H (1996) Use of percentiles for the body mass index in anorexia nervosa : diagnostic, epidemiological
- 20 and therapeutic considerations. *Int J Eat Dis* 19: 359-369.
- Hebebrand J, Hinney A, Roth H et al. (1998) Genetische Aspekte der Adipositas. In: J Wechsler (ed) *Adipositas*. Ex Libris Roche. Blackwell Verlag: 105-118.
- Hinney A, Schmidt A, Nottebom K, et al. (1999) Several mutations in the melanocortin-4 receptor gene including a nonsense and a frameshift mutation associated with
- 25 dominantly inherited obesity in humans. *J. Clin Endocrinol Metab.* Apr; 84(4):1483-1486.
- Hort Y, Baker E, Sutherland GR, Shine J, Herzog H (1995) Gene duplication of the human peptide YY gene (PYY) generated the pancreatic polypeptide gene (PPY) on chromosome 17q21.1. *Genomics* 26(1): 77-83.
- 30 Huszar D, Lynch CA, Fairchild-Huntress V, et al. (1997) Targeted disruption of the melanocortin-4 receptor results in obesity in mice. *Cell* 88:131-141.

Lander E and Kruglyak L (1995) Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. *Nat Genet*, 11(3):241-247.

Schneider R (1996) Relevanz und Kosten der Adipositas in Deutschland. *Ernährungs-Umschau* 43:369-374.

5 Stephens M, Smith NJ, Donnelly P (2001) A new statistical method for haplotype reconstruction from population data. *Am J Hum Genet* 68(4): 978-89

Vaisse C, Clément K, Guy-Grand B et al (1998) A frameshift mutation in human MC4R is associated with a dominant form of obesity. *Nat Genet* 20:113-114.

WHO (1998) Preventing and managing the global epidemic. WHO, Geneva.

10 Yeo GS, Farooqi IS, Aminian S, et al (1998) A frameshift mutation in MC4R associated with dominantly inherited human obesity. *Nat Genet* 20:111-112.

Wolf AM, Colditz GA (1996) Social and economic effects of body weight in the United States. *Am J Clin Nutr* 63(3 Suppl):466S-469S.

15 Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. (1994) Positional cloning of the mouse obese gene and its human homologue. *Nature* 372: 425-432.

CLAIMS

1. A method of detecting the presence of or predisposition to or protection from obesity or an associated metabolic disorder in a subject, the method comprising detecting the presence of an alteration in the PPY and/or PYY gene locus in a sample from the subject, the presence of said alteration being indicative of the presence of or the predisposition to, or the protection from obesity or an associated disorder.
2. A method of assessing the response of a subject to a treatment of obesity or an associated metabolic disorder, the method comprising detecting the presence of an alteration in the PPY and/or PYY gene locus in a sample from the subject, the presence of said alteration being indicative of a particular response to said treatment.
3. A method for preventing obesity or an associated disorder in a subject, comprising detecting the presence of an alteration in the PPY and/or PYY gene locus in a sample from the subject, the presence of said alteration being indicative of the predisposition to obesity or an associated disorder; and, administering a prophylactic treatment against obesity or an associated disorder.
4. The method of any one of claims 1 to 3, wherein said alteration in the PPY and/or PYY gene locus is selected from a mutation, a deletion and an insertion in the PPY gene locus.
5. The method of any one of claims 1 to 4, wherein the presence of an alteration in the PPY and/or PYY gene locus is detected by sequencing, selective hybridisation and/or selective amplification.
6. The method of any one of claims 1 to 5, wherein said alteration is one or several SNP(s) or an haplotype of SNPs associated with obesity.
7. The method of claim 6, wherein said haplotype associated with obesity comprises SNP4, SNP5 and SNP6.

8. The method of claim 6, wherein said SNP associated with obesity is SNP7 or SNP8.

**HUMAN OBESITY SUSCEPTIBILITY GENES ENCODING
POLYPEPTIDES OF THE NEUROPEPTIDE Y FAMILY AND
USES THEREOF**


ABSTRACT

10 The present invention discloses the identification of human obesity susceptibility genes,
which can be used for the diagnosis and prevention of obesity and related disorders. The
invention more specifically discloses that the PPY and PYY gene on chromosome 17
and certain alleles thereof are related to susceptibility to obesity. The present invention
relates to particular mutations in the PPY and PYY gene and expression products, as
15 well as to diagnostic tools and kits based on these mutations. The invention can be used
in the diagnosis of predisposition to or protection from, detection, prevention and/or
treatment of coronary heart disease and metabolic disorders, including
hypoalphalipoproteinemia, familial combined hyperlipidemia, insulin resistant syndrome
X or multiple metabolic disorder, coronary artery disease, diabetes and dyslipidemia.

20

BEST AVAILABLE COPY

FIGURE 1



SEQUENCE LISTING

<110> INTEGRAGEN

<120> HUMAN OBESITY SUSCEPTIBILITY GENES ENCODING POLYPEPTIDES OF THE NEUROPEPTIDE Y FAMILY AND USES THEREOF

<130> B0267US

<160> 5

<170> PatentIn version 3.1

<210> 1

<211> 501

<212> DNA

<213> homo sapiens

<220>

<221> misc_feature

<222> (425)..(425)

<223> SNP4 G/T

<400> 1	
ccaccgacct cctcccgggg ccccaggtag gacagcctgg atgctgggca ccgagccagg	60
ggcctcgggg ctgggggcag cttgggtgct agcgagagga agttcctggg ggcgggcatg	120
cggggagaca cagcaccct gtgggggggg cttctttctc caggctgggc cttggcctcc	180
agacgcctct ctgccacca acccctttgt attgagaggg gcctcgacce ctctcatcc	240
cctcagtga aacaataaag acaaattttt gttgcttcag tgacttctgt gggcctgcgg	300
gcagggaggg accagtccat ggaacgggaa gtgggaccct gtagtttctg ctgtgagaga	360

aaaagacctc agctgttggg ggtcctcccc tgcctcccct ggcaacccat ccaccttccc	420
ccackccacc cacacatggc cttgtgggtc tggccctcca ccccgtaggta gagacacaga	480
tacgggtcct ggagaagaca c	501

<210> 2

<211> 401

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (201)..(201)

<223> SNP5 A/G

<400> 2	
ctgggcaaga tggcgcctac aggcagatat gaaacagggtg ggctggcacc tgggcacagt	60
gcttgcccct gctgcctctt ccctcccagg tatgggaaaa gacacaaaga ggacacgctg	120
gccttctcgg agtgggggtc cccgcattgt gctgtcccca ggtgagtttg actccctgcc	180
ctgtctgtcc agctccctgg rgctgaaatg ggggtggtgg gactgaatca gggcttggaa	240
aggtgtagtg ggggtggaa gagggagaac aggagcccag ggccagcctg aggcctcctg	300
agggcacgag gcctaccccc tacactgcca tggtctgccc tgcctcaca gggagctcag	360
cccgtggac ttataatgcc accttctgtc tcctacgact c	401

<210> 3

<211> 401

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (201)..(201)

<223> SNP6 A/G

<400> 3
ttcccctgcc caacaccacg ccctctggca caaggtggat ggccactggc agtgatgggg 60
atggagtaag tgctatgaga ctaggagagg aacaccccag gaacacctga ggtcacagag 120
tgaatgaagg caggtaaagg agcaaaggga atgggggggc cccacatacg tgaccccagg 180
gcagcagctt ggctgcacc ragtcctcca tcacacacac tcccccgccc ccccccgca 240
tcctggctgt ctaaccacaa tcctgtctgc cttcagttaa tcaaccaatg agtgggcatt 300
cattgcacat ctgtttctggg cctcatgggg gcagcgggag gtgatgaaga agcaagggtt 360
ctacaaagag gtcaaagcta cgtgaggagc cggggaatgg c 401

<210> 4

<211> 1912

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (201)..(201)

<223> SNP7 C/T

<400> 4
ttgggtggcaa ttgtttgtca ttacaacctg gggcgcaaag tggaatccct gtcctctatc 60
caccgaggac ccctggggta ttttggcggc tggacctgcg ccctgagtcc aggaggctcg 120
atattcacc ttaggatatt ttctgaacc ccgatacccc acaatctcct atccgcacat 180
taactttacc ttgggatatg yaaatattaa gtagaaccct atgaaattta cattagttaa 240
ccgtttttgt ttggtttggg ttggtttggg tatgtttgag acagagtctc gctctgtcac 300
ccacgctgga ggcatctca gtcactgca acctccgct cccgggttca agtgattctc 360

ctgcctcagc ctcccagagta gctgggacca cagatgggta taacaatacc tcccatccca	420
catgcccttc cacaaggagg ccctgacatc tcccatcaag aaatgcagac gggccgggca	480
cgggtggctca cgcctgtaat cccagtgtt tgggaggccc aggtgggtgg atcacttgag	540
gtcaggaggtt caagaccagc ctgaccaaca tggtgaaacc ccgtctctac taaaaatata	600
aaaattagcc ggggtgtggtg gcaggcgct gtagtcccag ctacttggga ggctgaggca	660
agaggattgc ttgaaccag gaggcagagg ttgcggtgag ctgagcagcc actgcactcc	720
agcctgggtg aactccatc tcaatgaaaa aaaaaaaaaa aaacgaaaag aagagaaatg	780
caggcatgca ggcggcgaca gtggctcacg cctgtaatcc caacactttg ggaggccaag	840
gcagttggat cgcttgagct caggagttta agactagctg ggcaacatag caaaactctg	900
tctctacaaa aaaagaaaga aaaaaattat atatatatat gaaagaaatg cagcccatga	960
cttcccttga gtctgggtggg cttgtgacac acttataacc aataggatgg gtcagaagta	1020
atgctacagg actgctaagg ttgaacttta aaagacaatg cagcagccac cttttctgct	1080
ggaccaggtg ggcttgaagc ctccagctgc cctgtaagca gcccaactgc cctgaagctg	1140
ctccaaatca gcctgcccag agagaccact ctgagactac gtggagagag agagagagat	1200
gcttgtccag cccctggac ccaggcccca cccttgctgt ccagctcca gccatcatct	1260
gactgcaacc acatgagaaa ctctgaacta gaaccaccag gtaagccctt cctgaattcc	1320
tcattggagag catccatgag caaataaaat gggtctttca agccatgggg ttttggggta	1380
attttcattt ttgagacag tgtctcactc tgtcaccag gctggagtgc agtgggtgtaa	1440
tctcagccca ctgcaacctc cactcctgg caggatgatc tctacctca gcctcccaag	1500
cagctgggac cacatatgtc caccaccaga cctggctaatt ttcttgtttt ttatttttac	1560
tttatgctgg gtttttttgt ttttggtggt ttgtttatgt gttcatttgt ttgagacag	1620
ggtcttgctc tggtgcccga gctggagtgc agtggcgcaa tctcagctca ctgcaacccc	1680
cactcctgg gcttaggcca tctcccacc tcagccaccc gagtaggaac tacaggcgca	1740
caccaccag cccagctaatt ttttgatatt ttttatagag acaaggtttt gccatgttgc	1800
ccaggctggg ctcaaattcc tgagctcaag caatgtacct gcctcagcct cccaaagtgc	1860
tgggattaca ggtatgagcc actgcacgtg gcctaatttt ttacagtttc tt	1912

<210> 5

<211> 401

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (321)..(321)

<223> n = a, t, g or c

<220>

<221> misc_feature

<222> (201)..(201)

<223> SNP8 C/T

<400> 5
gccttgccct aaaaactgtg tctacatca cctccccaca cccaggtact tcaaacacag 60
tgatggcagc ttctccaaca gcagtggatc ttcttctggt ttggcctggc tgatatccgg 120
gactcctatg agttggtcaa ccacgccaag ggactgccag actcctttca caagccagct 180
tctgacctag gcagctgacc ytcaccatgg acactacagg ccgggggggtg gccaggggtg 240
accaaaagcc atgccagctg ggcattgaccc caggcagcca gccacaggct gaagggggct 300
tgttggctga gtgatctgca naggagaaag cagccccagc tctgcccaga ggaggcgctg 360
aagtgggaca agcacaggaa agaagggggac cagtctagga c 401